Bristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It Matters

Impact · against what's priced in

Positive Phase 3 results for iza-bren in NSCLC provide a concrete growth catalyst for BMY, nearly doubling median progression-free survival compared to chemotherapy. While the drug requires multi-billion dollar milestone payments, the clinical efficacy across five solid tumor types strengthens the company's transition toward its growth portfolio.

BMY+0.60

No priced-in read yet